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Depending on endoplasmic reticulum (ER) stress
levels, the ER transmembrane multidomain protein
IRE1a promotes either adaptation or apoptosis.
Unfolded ER proteins cause IRE1a lumenal domain
homo-oligomerization, inducing trans autophosphor-
ylation that further drives homo-oligomerization of its
cytosolic kinase/endoribonuclease (RNase) domains
to activatemRNAsplicingof adaptiveXBP1 transcrip-
tion factor. However, under high/chronic ER stress,
IRE1a surpasses an oligomerization threshold that
expands RNase substrate repertoire to many ER-
localized mRNAs, leading to apoptosis. To modulate
these effects, we developed ATP-competitive IRE1a
Kinase-Inhibiting RNase Attenuators—KIRAs—that
allosterically inhibit IRE1a’s RNase by breaking oligo-
mers. One optimized KIRA, KIRA6, inhibits IRE1a
in vivo and promotes cell survival under ER stress. In-
travitreally,KIRA6preservesphotoreceptor functional
viability in rat models of ER stress-induced retinal
degeneration. Systemically, KIRA6 preserves pancre-
atic b cells, increases insulin, and reduces hypergly-
cemia in Akita diabetic mice. Thus, IRE1a powerfully
controls cell fate but can itself be controlledwith small
molecules to reduce cell degeneration.534 Cell 158, 534–548, July 31, 2014 ª2014 Elsevier Inc.INTRODUCTION
Secreted and transmembrane proteins fold and assemble in the
endoplasmic reticulum (ER) through reactions catalyzed by
ER-resident activities. When these reactions are saturated or
corrupted, cells experience ‘‘ER stress,’’ and unfolded protein
accumulation in the ER triggers intracellular signaling pathways
termed the unfolded protein response (UPR). The UPR induces
transcription of genes encoding ER chaperones, oxidoreduc-
tases, and ER-associated degradation (ERAD) components
(Travers et al., 2000), while inhibiting translation (Harding et al.,
2000). These outputs are adaptive because they enhance ER
protein-folding capacity, reduce secretory protein load, and pro-
mote degradation of ER unfolded proteins.
However, if ER stress remains irremediably high and adaptive
outputs are overwhelmed, alternative ‘‘terminal UPR’’ signals
trigger apoptosis. Although cell death under high ER stress
may protect organisms from exposure to improperly folded
secretory proteins, many human degenerative diseases, such
as diabetesmellitus and retinopathies, may be caused by exces-
sive ER stress-induced cell death (Shore et al., 2011). Mecha-
nistic understanding of critical terminal UPR signaling events
may lead to effective therapies for such conditions.
Unfolded ER proteins activate three ER transmembrane sen-
sors—PERK, ATF6, and IRE1a—by changing their oligomeriza-
tion state in the ER membrane (Kohno, 2007). IRE1a, the
most ancient of these components, senses unfolded proteins
either directly or indirectly through an ER lumenal domain that
becomes oligomerized during stress (Credle et al., 2005; Zhou
et al., 2006). Subsequently, IRE1a’s bifunctional kinase/endori-
bonuclease (RNase) activities become juxtaposed on its cyto-
solic face, allowing monomers to trans-autophosphorylate.
Kinase autophosphorylation conformationally activates IRE1a’s
RNase to site-specifically cleave the XBP1 mRNA. Religation
and translation of XBP1 mRNA in an alternate open reading
frame produces the XBP1s transcription factor, whose targets
encode proteins that enhance ER protein folding and quality
control (Calfon et al., 2002; Lee et al., 2003; Yoshida et al.,
2001). Thus, IRE1a promotes adaptation via XBP1s.
However, under high ER stress, IRE1a’s RNase relaxes its
substrate specificity to endonucleolytically cleave many other
mRNAs that localize to the ER membrane as their encoded pro-
teins undergo cotranslational translocation (Han et al., 2009; Hol-
lien et al., 2009). IRE1a’s RNase also cleaves precursors of
apoptosis-inhibitory microRNAs (Lerner et al., 2012; Upton
et al., 2012).
Here, we show that multiple terminal UPR outputs, including
cell proliferation blocks, sterile inflammation, and apoptosis
result from kinase-driven increases in the oligomerization state
of IRE1a’s cytosolic domains that hyperactivate its RNase.
These destructive events are prevented by breaking IRE1a olig-
omerization through rational mutations or somatic mutations
found in the Ire1a gene of various human cancers. To test
physiological effects of pharmacologically inhibiting IRE1a, we
developed small-molecule kinase inhibitors that prevent oligo-
merization and allosterically inhibit its RNase. One such IRE1a
kinase inhibitor preserves viability and function in ER-stressed
cells, pancreatic islet explants, and rodent models of ER
stress-induced retinitis pigmentosa and diabetes.
RESULTS
IRE1a’s Kinase Is a Rheostat that Employs Self-
Association to Control RNase Activity
Previously, we proposed that IRE1a’s kinase regulates catalytic
activity of its adjoining RNase in a graduated manner to impact
cell fate in mammals, yet the mechanistic basis for the rheostatic
control remained unclear (Han et al., 2009). Here, we hypothe-
sized that the degree of self-association of kinase/RNase sub-
units on the cytosolic face connects IRE1a phosphorylation
status to RNase activation levels. Increasing phosphorylation
of the IRE1a kinase may proportionally increase the oligomeric
state of kinase/RNase subunits past a critical threshold, thereby
driving RNase activity into a hyperactive state. Consequently,
IRE1a RNase expands its specificity past its canonical XBP1
mRNA substrate, endonucleolytically cleaving many ER-local-
ized mRNAs and pushing cells into apoptosis. In this view,
IRE1a’s lumenal domains are responsive to protein-folding con-
ditions in the ER, but rheostatic control by the kinase over the
RNase ultimately determines cell fate. If these predictions are
correct, genetic and small-molecule control over IRE1a kinase
oligomerization should enable cell fate control, irrespective of
upstream ER stress.
To begin testing this hypothesis, we employed IRE1a recom-
binant proteins and cell lines. Artificial ER stress agents are
widely used to acutely activate the UPR, but saturating dosesthat have no natural pathophysiological correlate are often em-
ployed. To test cytoprotection later in the work, we established
dose-response regimes using three ER stress agents that
dose-dependently push rat insulinoma (INS-1) cells, which
have a well-developed ER and secrete insulin, past a stress
threshold and, in switch-like manner, into apoptosis. The per-
centage of INS-1 cells entering apoptosis due to the ER Ca2+
pump inhibitor thapsigargin (Tg) depends aggregately on two
variables: concentration and duration of exposure (Figures S1A
and S1B available online). Similar results hold for the glycosyla-
tion inhibitor tunicamycin (Tm) and the anterograde trafficking
inhibitor brefeldin A (BFA) (Figures S1C and S1D). Preceding
apoptosis, increasing ER stress agent levels progressively in-
crease IRE1a phosphorylation, XBP1 mRNA splicing, endonu-
cleolytic decay of the ER-localized mRNA, Ins1 mRNA (which
encodes proinsulin), induction of thioredoxin-interacting protein
(TXNIP) mRNA (whose product activates the NLRP3 inflamma-
some), and downstream c-Jun terminal kinase (JNK) phosphor-
ylation (Figures S1E and S1F).
All of these terminal UPR signature events, culminating in
apoptosis, can be simulated, without imposing ER stress, by
conditionally overexpressing wild-type (WT) IRE1a in INS-1 sta-
ble lines (Han et al., 2009). Induced with doxycycline (Dox), the
transgenic IRE1a (WT) proteins spontaneously self-associate,
trans-autophosphorylate, and trigger XBP1 mRNA splicing (Fig-
ures 1A and 1B) (Han et al., 2009). Increasing [Dox] causes pro-
gressive decay of Ins1 mRNA, elevation of TXNIP mRNA, and
apoptosis (Figures 1C and 1D). Thus, as with ER stress agents,
dose escalation of transgenic IRE1a (WT) allows graduated con-
trol over the terminal UPR and is sufficient to push cells, in
switch-like manner, into apoptosis (Figure 1E).
To study how IRE1a autophosphorylation impacts oligomeric
state and RNase substrate selectivity, we expressed and purified
a recombinant soluble miniprotein—called IRE1a*—containing
the kinase/RNase domains. Salt bridges formed through phos-
phoamino groups in neighboring IRE1a kinases contribute to
kinase/RNase homo-oligomerization (Ali et al., 2011; Korennykh
et al., 2009). IRE1a* is basally autophosphorylated and sponta-
neously homo-oligomerizes as its concentration is raised
(Figures 1F and 1G). Dephosphorylation of IRE1a* with l-phos-
phatase—dP-IRE1a*—reduces the oligomer/monomer ratio,
confirming that phosphorylation drives oligomerization.
We next tested the impact of IRE1a* oligomerization on
RNase activity against in-vitro-transcribed XBP1 RNA and a
less efficient substrate, Ins2 RNA, derived from one of the two
mRNA isoforms encoding rodent proinsulin (Figures 1H and
1I). We also utilized an IRE1a* variant whose oligomeric state
can be controlled with a small molecule. Mutation of IRE1a*
at the isoleucine (I) gatekeeper residue to glycine (G) in its ki-
nase ATP-binding pocket creates a ‘‘hole’’—IRE1a* (I642G); in
the full-length protein, the I642G mutation cripples autophos-
phorylation (Han et al., 2009). As with dP-IRE1a*, IRE1a*
(I642G) has reduced oligomerization compared to IRE1a* (Fig-
ures 1F and 1G). 1NM-PP1 is a ‘‘bumped’’ kinase inhibitor
that selectively binds mutant kinases that contain glycine gate-
keeper residues. Working as a ligand, 1NM-PP1 increases
IRE1a* (I642G) oligomerization but to levels well below those
of equimolar IRE1a*.Cell 158, 534–548, July 31, 2014 ª2014 Elsevier Inc. 535
Figure 1. IRE1a’s Kinase Uses Homo-Oligomerization as a Rheostat to Control RNase Activity and Apoptosis
(A) Anti-phospho-IRE1a and anti-Myc immunoblots (ratiometric quantitation, normalized to GAPDH).
(B) Agarose gel of PstI-digested XBP1 cDNA amplicons (ratiometric quantitation of spliced to total XBP1 cDNAs).
(C) qPCR for Insulin1 (Ins1) and TXNIP mRNAs.
(D) Percent of Annexin-V positive staining. (A)–(C) utilized INS-1::IRE1a (WT) cells under increasing [Dox] at 24 hr, whereas (D) is at 72 hr.
(E) Model of how IRE1a promotes both adaptive and apoptotic outputs.
(F and G) (F) Immunoblots of increasing concentrations of IRE1a*(WT), dP-IRE1a*(WT), and IRE1a*(I642G) /+ 1NM-PP1 (10 mM) followed by disuccinimidyl
suberate (DSS) (250 mM) crosslinking with oligomer/monomer quantification (G).
(legend continued on next page)
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Consistent with partial increases in oligomeric state, RNase
activity is revived in 1NM-PP1-bound IRE1a* (I642G) but with
activity largely confined to XBP1 RNA (Figures 1H and 1I). There-
fore, both IRE1a* and 1NM-PP1-bound IRE1a* (I642G) efficiently
cleave XBP1 RNA, but only IRE1a* surpasses the oligomeriza-
tion threshold needed to catalyze the more sluggish Ins2 RNA
cleavage reaction (Figure 1J). Thus, oligomerization state
directly impacts IRE1a’s RNA substrate specificity.
We next tested effects in vivo. Upon self-association of its
lumenal domains when expressed in an INS-1 line, IRE1a
(I642G) fully splices XBP1 mRNA under 1NM-PP1 without ER
stress and without causing Ins1 mRNA decay or apoptosis (Fig-
ure S1G). In fact, without 1NM-PP1, IRE1a (I642G) even reduces
apoptosis under ER stress, acting as a strong dominant negative
(Figure S1H). Another kinase-dead mutant, IRE1a (K599A)
(which is also RNase dead), and an RNase-dead mutant, IRE1a
(N906A), are also strongly dominant negative for apoptosis
(Figure S1H).
We previously showed that, by pre-emptively producing
XBP1s, 1NM-PP1-activated IRE1a (I642G) provides a meta-
stable degree of cytoprotection against subsequent ER stress
(Han et al., 2008, 2009), as does forced expression of XBP1s,
shown here (Figure S1I). However, without a window of sufficient
time to permit adaptive preconditioning, simultaneous provision
of 1NM-PP1 and ER stress agents rescues Ins1 mRNA decay
and apoptosis in a 1NM-PP1 dose-dependent manner (Figures
S1J and S1K).
Further supporting the notion that IRE1a triggers apoptosis
using its RNase, a ‘‘holed’’-RNase-dead double mutant—IRE1a
(I642G/N906A)—remains dominant negative under 1NM-PP1
(Figure S1L). In aggregate, the chemical-genetic studies show
that the oligomeric state of IRE1a kinase/RNase subunits
impacts both RNA substrate selection and cell fate and that
discrete, intermediate activation states are available to the
effector catalytic domains (Figure S1M).
Divergent Allosteric Modulation of IRE1a Oligomeric
State and RNase Activity with Distinct Kinase Inhibitors
As with the rationally engineered mutants, we find that interme-
diate activation states in IRE1a occur naturally through rare
somatic Ire1a genemutations found in human cancers, including
glioblastoma, lung adenocarcinoma, and serous ovarian cancer
(Greenman et al., 2007). We predicted that five mutations span-
ning the kinase and RNase should affect function: four are
missense, and one, Q780D, which is nonsense, amputates the
entire RNase (Figure 2A). Expressed conditionally in isogenic
INS-1 lines, the human IRE1a cancer mutants are all compro-
mised for apoptosis (Figure 2B). Normalized to WT, the muta-
tions significantly abrogate autophosphorylation and XBP1
splicing (Figures 2C–2E). Expression of severely crippled IRE1a
(Q780D) or IRE1a (P830L) actually increases Ins1 mRNA levels
(Figure 2F), suggesting that some basal decay may even be(H and I) (H) Time course urea PAGE of cleavage of a32P-labeled XBP1 RNA and In
quantification (I).
(J) Model of oligomerization dependence of RNase activity against XBP1 and Ins2
were used for XBP1 splicing, qPCR, and Annexin V experiments. Data are plotte
See also Figure S1.blocked. Cells expressing IRE1a (Q780D) or IRE1a (P830L) pro-
liferate well, in contrast to those expressing IRE1a (WT) or
parental lines under ER stress (Figure 2H) (Movies S1, S2, S3,
S4, S5, and S6). The mRNA encoding cyclin-dependent kinase
inhibitor p21 is strongly induced in cells expressing IRE1a
(WT), but not IRE1a (Q780D) or IRE1a (P830L) (Figure 2I).
Marking cycling cells, Ki67 sharply declines upon expression
of IRE1a (WT), but not IRE1a (Q780D) or IRE1a (P830L)
(Figure 2J).
Lack of the RNase in IRE1a (Q780D) converts it into a domi-
nant negative (Figures S2A–S2D). The P830L mutation, which
occurs at the kinase/RNase junction (Figure 2G), may destabilize
a dimerization interface (Xue et al., 2011). We predicted and
tested that RNase activity in IRE1a (P830L) can be rescued
with a kinase inhibitor, as IRE1a (I642G) can with 1NM-PP1.
We previously employed two distinct classes of kinase inhibi-
tors—types I and II—to stabilize alternate kinase active site con-
formations in IRE1a (Wang et al., 2012). APY29 is a type I kinase
inhibitor of IRE1a that stabilizes an active kinase domain confor-
mation, which is typically adopted by ATP-bound kinases. By
stabilizing the active kinase conformation, type I inhibitors act
as ligands that allosterically activate IRE1a’s RNase—e.g.,
1NM-PP1 is a type I inhibitor of IRE1a (I642G).
Compared to IRE1a* (WT), IRE1a* (P830L) has reduced kinase
activity (Figure 3A), as the full-length protein does in vivo (Fig-
ure 2C). APY29 dose-dependently suppresses residual auto-
phosphorylation of IRE1a* (P830L) (Figure 3B). IRE1a* (P830L)
cannot cleave a FRET-quenched XBP1 RNA minisubstrate
(Han et al., 2009) (Figures 3C–3E), which is consistent with
reduced RNase activity in vivo (Figure 2D). But, opposite to
effects on kinase activity, APY29 increases IRE1a* (P830L)’s
oligomeric state to rescue RNase activity (Figures 3D–3G).
If, as all preceding results suggest, kinase-driven oligomeriza-
tion of IRE1a hyperactivates its RNase to trigger apoptosis, then
kinase inhibitors that block oligomerization should prevent
apoptosis under ER stress. To this end, we employed type II
kinase inhibitors that stabilize an inactive ATP-binding site
conformation in IRE1a. We previously developed a subset of
type II kinase inhibitors designated KIRAs, for kinase-inhibiting
RNase-attenuators, that inhibit IRE1a’s RNase activity by
breaking oligomers (Wang et al., 2012). Since our original report,
we have identified KIRA6 as a more potent version (Figure 3H).
KIRA6 dose-dependently inhibits IRE1a* (WT) kinase activity,
XBP1 RNA cleavage, Ins2 RNA cleavage (with lower IC50 than
for XBP1 RNA in a competition assay), and oligomerization (Fig-
ures 3I–3L).
To follow IRE1a oligomerization in vivo, we first tested a re-
porter called IRE1-3F6HGFP that contains an EGFP domain
positioned near the kinase (Li et al., 2010), but found that it has
attenuated XBP1 splicing and fails to induce apoptosis (Figures
S3A and S3B). To avoid potential steric effects on the kinase, we
constructed a superfolder green fluorescent protein (sfGFP)sulin2 (Ins2) RNA by IRE1a*(WT) and IRE1a*(I642G)/+ 1NM-PP1 (10 mM), with
RNAs by IRE1a*(WT) and IRE1a*(I642G). Three independent biological samples
d as mean value ± SD. *p < 0.05 and **p < 0.01, ns, not significant.
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Figure 2. IRE1a Cancer Mutants Are Disabled for Apoptosis
(A) Cancer-associated mutations in human IRE1a.
(B) TimecourseAnnexin-Vstainingof INS-1cells stablyexpressinghuman IRE1a (WT), (L474R), (R635W), (S765F), (Q780*), and (P830L) undersaturatingDox (1mg/ml).
(C and D) (C) Anti-phospho-IRE1a and anti-Myc immunoblots and (D) agarose gel of PstI-digested XBP1 cDNA amplicons from INS-1 cells expressing human
IRE1a (WT) and mutants with Dox (1 mg/ml) for 24 hr.
(E) XBP1 splicing from (D) as a function of IRE1a phosphorylation from (C).
(F) Time course qPCR of Ins1 mRNA from INS-1 cells expressing IRE1a (WT) and mutants under Dox (1 mg/ml).
(G) Cartoon of monomeric human IRE1a (P830L) (right) and IRE1a (Q780*) dimerized with a IRE1a (WT) subunit (left) based on PDB: 3P23.
(H) Time course MTT staining of INS-1 cells expressing IRE1a (WT), IRE1a (P830L), or IRE1a (Q780*) /+ Dox (1 mg/ml) or parental INS-1 cells /+ 100 nM Tg.
(I and J) Time course qPCR for p21mRNA and Ki67 staining from INS-1 IRE1a (WT), IRE1a (P830L), or IRE1a (Q780*) cells under Dox (1 mg/ml). Three independent
biological samples were used for qPCR, Ki67, and Annexin V experiments. Data are plotted as mean ± SD.
See also Figure S2.
538 Cell 158, 534–548, July 31, 2014 ª2014 Elsevier Inc.
Figure 3. Divergent Modulation of IRE1a RNase Activity Using Distinct Classes of Kinase Inhibitors
(A) Phosphorimager analysis of human IRE1a* (25 nM) and IRE1a* (P830L) (25 nM) kinase activity against peptide substrate (PAKtide, 2 mM) in the presence
of 32Pg-ATP.
(B) Autoradiogram of IRE1a* (P830L) autophosphorylation under increasing [APY29].
(C) 50 FAM-30 BHQ XBP1 minisubstrate to measure RNase activity.
(D) RNase activities of IRE1a* and IRE1a* (P830L) /+ APY29 (20 mM) per (C).
(E) Urea PAGE of XBP1 cleavage products from (D).
(F) Immunoblots of increasing IRE1a* (P830L) after incubation with DMSO or APY29 (200 mM) and DSS with oligomer/monomer quantification.
(G) Model of APY29 rescue of oligomerization and RNase activity in IRE1a* (P830L).
(legend continued on next page)
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N-terminally fused to the ER lumenal domain. Expressed iso-
genically in INS-1 cells, sfGFP-IRE1a retains apoptotic activity
and gathers into discrete fluorescent foci in the ER membrane
under the ER stress agent dithiothreitol (DTT) (Figures 3M,
S3A, and S3B). A (I642G) version of sfGFP-IRE1a fully splices
XBP1 mRNA under 1NM-PP1 without forming foci (Figures
S3C and S3D). In fact, without 1NM-PP1, sfGFP-IRE1a (I642G)
resists forming foci under DTT, suggesting that, without its
ligand, it adopts an inactive kinase conformation and explains
dominant-negative effects of IRE1a (I642G) (Figure S1H). Similar
to apoptosis, foci formation by sfGFP-IRE1a (I642G) requires
both ER stress and 1NM-PP1, further supporting the tight link
between IRE1a oligomerization—shown in vivo through foci—
and apoptosis. Thus, using sfGFP-IRE1a, which faithfully reca-
pitulates cytosolic events, we tested and found that KIRA6
prevents foci formation by DTT (Figure 3M). Hence, KIRAs fulfill
their design principle of breaking kinase/RNase oligomers to
inhibit the RNase (Figure 3N).
KIRA6 Inhibits IRE1a In Vivo to Preserve Cell Viability
and Function in Diverse Cells and Rodent Tissues
Experiencing ER Stress
The remainder of our work focused on testing physiological
effects of IRE1a kinase inhibition. APY29 showed pleiotropic
toxicity, including proliferative blocks at lowmicromolar concen-
trations, precluding further in vivo testing of ON-target effects
(Figure S4A). In contrast, KIRA6 had negligible toxicity up to
10 mM (Figure S4A), providing a favorable therapeutic index to
test cytoprotection. INS-1 lines confirmed ON-target effects:
pro-Caspase-3 cleavage upon IRE1a (WT) expression is pre-
vented by KIRA6 (Figure 4A). Moreover, despite its inability to
directly inhibit JNK activity in vitro, KIRA6 strongly inhibits JNK
phosphorylation from IRE1a hyperactivation or ER stress (Fig-
ures 4A–4C). Also, KIRA6 dose-dependently inhibits Ins1
mRNA decay, proinsulin depletion, and apoptosis from IRE1a
hyperactivation (Figures 4D–4F).
Chemical-genetic tools enabled ON-target competition tests.
KIRA6 (1) reduces 1NM-PP1-induced XBP1 RNA cleavage by
IRE1a* (I642G) in vitro (Figure 4G); (2) antagonizes 1NM-PP1-
induced XBP1 splicing by IRE1a (I642G) in vivo (Figure 4H);
and (3) reduces 1NM-PP1 potentiation of Ins1 mRNA decay
and apoptosis during ER stress in a dose-dependent manner
(Figures 4I, S4B, and S4C). KIRA6 does not inhibit the activity
of a panel of Ser/Thr kinases (including JNK2 and 3) in vitro
(Figure S4D). Moreover, KIRA6 does not inhibit or secondarily
promote eIF2a phosphorylation by PERK, the other UPR kinase
(Figure S4E).
Having confirmed that KIRA6 has ON-target effects, we next
tested efficacy against endogenous IRE1a using the established(H) Structure of KIRA6.
(I) KIRA6 inhibition of IRE1a* kinase activity. IC50 values by fitting percent kinase
(J and K) (K) Urea PAGE of competition cleavage by IRE1a* of XBP1 RNAminisubs
in-gel fluorescence intensities (XBP1) and phosphorimager (Ins2).
(L) Immunoblots of increasing [IRE1a*] incubated with DMSO or KIRA6 (10 mM) a
(M) Left, cartoon of sfGFP-IRE1a reporter. Right, images of sfGFP-IRE1a induce
1 hr /+ KIRA6 (1 mM). Scale bar, 5 mm.
(N) Model for how KIRA6 lowers oligomeric status and RNase activity of IRE1a*.
Also see Figure S3.
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trigger point (Figures S1A–S1D). In INS-1 cells, KIRA6 inhibits
IRE1a autophosphorylation by Tg and XBP1 mRNA splicing by
Tm in a dose-dependent manner (Figures 5A–5C), whereas a
control analog, (NMe)KIRA6, incapable of binding to the kinase
hinge region inhibits neither output at 10 mM (Figures 5A, 5B,
S5A, and S5B).
We next tested multiple terminal UPR endpoints and found
that KIRA6: (1) inhibits Ins1 and Ins2 mRNA decay by Tm in
INS-1 cells in a dose-dependent manner (Figures 5D and S5C).
We noted that the in vivo IC50 of KIRA6 for Ins1 mRNA rescue
is lower than that for inhibiting XBP1 splicing, and Ins2 mRNA
levels recover even at 20 nM KIRA6 and exceed basal, untreated
levels in a dose-dependent manner. Furthermore, KIRA6 (2) in-
hibits TXNIP induction by Tm in murine C57BL/6 pancreatic
islets (Figure 5E); (3) inhibits IRE1a-dependent activation of a
TXNIP 30 UTR luciferase reporter containing its twomiR-17 bind-
ing sites (Figure S5D); (4) prevents 1L-1b secretion by Tm and Tg
(but not ATP) in THP1 macrophage lines (Figure 5F); (5) prevents
loss of INS-1 Ki67-positive cells and C57BL/6 pancreatic islet
double-positive Nkx6.1/EdU b cells under ER stress (Figures
5G, 5H, and S5E) (Movie S7); (6) dose-dependently inhibits
apoptosis of INS-1 cells under BFA (Figure 5I); (7) reduces
TUNEL staining of b cells in C57BL/6 and human islets under
Tm (Figures 5J and S5F); and (8) preserves glucose-stimulated
insulin secretion (GSIS) in C57BL/6 islets under Tm (Figure 5K).
We also tested effects of STF-083010, a small-molecule tool
compound that reactively modifies Lysine 907 in the RNase
active site (Papandreou et al., 2011) (Figure S5G). As with
KIRA6, STF-083010 (at 50 mM) also decreases Ins1mRNA decay
under IRE1a hyperactivation and apoptosis by Tm (Figures S5H
and S5I). Moreover, when used in combination at doses that are
subtherapeutic individually, STF-083010 (1 mM) and KIRA6
(50 nM) afford significant cytoprotection under Tm (Figure S5J).
Together, these data further implicate IRE1a’s RNase in promot-
ing apoptosis, in this case by showing that the RNase can even
be inhibited combinatorially through two distinct sites in IRE1a
for cytoprotection.
To rule out the possibility that KIRA6 defeats ER stress agents
upstream of IRE1a, we tested whether blocks to ER posttransla-
tional modification still persist under KIRA6. A test substrate, the
null Hong Kong variant of alpha-1 anti-trypsin (NHK-A1AT), nor-
mally glycosylated and ER-retained, is deglycoslyated under
Tm. NHK-A1AT clearly remains deglycoslyated under both Tm
and KIRA6 (Figure 5L).
Encouraged by clear and convincing evidence that KIRA6 pre-
serves cell viability and function in multiple cell and explant sys-
tems under diverse ER stress regimes, we next applied a higher
evidentiary standard by testing disease-relevant animal models.activity per assay in (A) (n = 3).
trate (J) and a32P-labeled Ins2 RNA (K) under indicated [KIRA6]; IC50s by fitting
nd DSS with oligomer/monomer quantification.
d with (subapoptotic) 1 ng/ml Dox for 24 hr in INS-1 cells /+ DTT (5 mM) for
Data are plotted as mean ± SD.
Figure 4. KIRA6 Inhibits IRE1a Terminal UPR Outputs and Apoptosis
(A) Anti-total JNK, anti-phospho-JNK, and anti-Pro- and cleaved Caspase-3 immunoblots of INS-1 IRE1a (WT) cells treated with Dox (5 ng/ml) /+ 1 mM KIRA6
for 72 hr.
(B) JNK2a1 phosphorylation under indicated [KIRA6] by in vitro ELISA-based anti-phospho-JNK assay.
(C) Anti-total and phospho-JNK immunoblots of INS-1 cells pretreated for 1 hr with indicated [KIRA6] and then 1 mM Tg for 2 hr.
(D) qPCR for Ins1 mRNA in INS-1 IRE1a (WT) cells treated with Dox (5 ng/ml) /+ KIRA6 (1 mM).
(E) Anti-proinsulin immunoblot of samples in (A).
(F) Percentage of Annexin V staining in INS-1 IRE1a (WT) cells after 72 hr in Dox (5 ng/ml) and indicated [KIRA6].
(G) Competition between indicated [1NM-PP1] and KIRA6 (1 mM) for IRE1a* (I642G) RNase.
(legend continued on next page)
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Given compelling evidence that ER stress contributes to photo-
receptor loss inmany retinal diseases, including retinitis pigmen-
tosa (RP) (Zhang et al., 2014), we tested KIRA6 in two rodent
models. Transgenic rats expressing a misfolded Rhodopsin
mutant (P23H) exhibit spontaneous photoreceptor degeneration
and are a model of autosomal dominant RP (Gorbatyuk et al.,
2010). Retinas of hemizygous P23H rats develop normally but
lose photoreceptors beginning on postnatal day (P) 10; by P40,
the outer nuclear layer (ONL), representing photoreceptor nuclei,
is reduced to 50% of the thickness of WT rats (Pennesi et al.,
2008). We intravitreally injected KIRA6 or carrier into either eye
of individual P23H rats at P9 and P15. ONL thickness at P40 re-
vealed partial yet statistically significant protection from photo-
receptor loss in KIRA6-treated eyes (Figures S6A and S6B).
Given rapid clearance of intravitreally injected small molecules
(half-life < 60 hr), we were unable to maintain sufficient KIRA6 in
the vitreous over the30 day progression of retinal degeneration
in P23H rats to test for functional protection. Therefore, we used
a model of acute photoreceptor loss occurring over 7 days from
a single intravitreal injection of Tm into adult rats (Shimazawa
et al., 2007). Intravitreal coinjection of KIRA6 with Tm signifi-
cantly reduces XBP1 splicing, TXNIP induction, and decay of
the ER-localized photoreceptor-specific Rhodopsin mRNA
(Figures 6A–6C). Rhodopsin mRNA may be an IRE1a RNase
substrate because Rhodopsin RNA is cleaved by IRE1a*, but
not RNase-dead IRE1a* (N906A), at a G/C site with flanking sim-
ilarity to scission sites in XBP1 (Figure S6C). KIRA6 dose-depen-
dently inhibits Rhodopsin RNA cleavage by IRE1a* (Figures 6F
and 6G). Concomitant with blockage of terminal UPR outputs,
coinjection of KIRA6 in the Tm model reduces photoreceptor
loss by optical coherence tomography (OCT) and histology
(Figure 6H).
Next, to test whether KIRA6 also provides functional protec-
tion, we established a dose-response curve to determine
threshold [Tm] that causes functional retinal damage as
measured by scotopic electroretinograms (ERG) (Figure 6I).
Based on the results, we injected Tm at 3 mg/ml. In this regime,
coinjection with KIRA6 substantially protects against loss of
ERG responsiveness, significantly preserving both a and b
wave amplitudes (Figures 6J, 6K, and S6D).
Finally, to test in vivo efficacy of systemic KIRA6, we chose the
Ins2+/Akita (Akita) mouse, which expresses a mutant (C96Y) pro-
insulin unable to complete oxidative folding, thus causing
chronic ER stress, b cell apoptosis, and diabetes in infancy
(Lerner et al., 2012). The pharmacokinetic profile of KIRA6 in
BALB/c mice intraperitoneally (i.p.) dosed at 10 mg/kg showed
good drug plasma AUC levels (AUC 0–24 hr = 14.3 mM*h)
with moderate clearance (22.4 ml/min/kg). Drug half-life was
3.90 hr, Cmax was 3.3 mM, and plasma levels at 4 and 8 hr
were 1.2 mM and 0.33 mM, respectively. Initial systemic studies
utilized a Tm i.p. challenge in C57BL/6 mice, with and without
KIRA6 coinjection, and UPR markers measured in liver. Low-(H) Agarose gel of PstI-digested XBP1 cDNA amplicons from INS-1 cells IRE1a
indicated [KIRA6] for 3 hr with quantitation.
(I) Annexin V staining of INS-1 IRE1a (I642G) cells after 72 hr with Dox (1 mg/ml),
(J) Model of 1NM-PP1 and KIRA6 competition of oligomerization and RNase activ
See also Figure S4.
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of ER-localized Blos1 mRNA (Hollien et al., 2009), whereas
KIRA6 coprovision reduces XBP1 splicing (Figures S7A and
S7B). Escalation of Tm to 100 mg/kg further increases XBP1
splicing and triggers Blos1 mRNA decay, with both markers
attenuated by KIRA6 (Figures S7C and S7D).
Based on low micromolar KIRA6 needed for protection in cell
culture, we chose i.p. dosing regimens of 5 or 10 mg/kg twice a
day (b.i.d.) for Akita chronic efficacy studies to provide similar
exposure. We injected KIRA6 into randomized 3-week-old
male Akita mice when their random blood glucose levels were
at prediabetic range (200 mg/dl). In both dosing regimes, we
observed significant amelioration of random glucose levels
over several weeks in KIRA6-treated mice compared to vehicle,
both fed ad lib (Figures 7A and S7E). TXNIP mRNA levels decline
in islets of KIRA6-treated mice within 1 week without compensa-
tory increase of CHOP mRNA (downstream of PERK) (Figures
S7G and S7H). KIRA6-treated mice appeared healthy even after
49 days from initial injection and displayed no significant differ-
ences in weight from vehicles (Figures 7B and S7F). Even
12 days after stopping injections, the 5 mg/kg KIRA6-treated
mice show significantly improved random blood glucose levels
and glucose tolerance tests (GTT) (Figure 7C). Even 21 days af-
ter stopping injections, KIRA6-treated mice display statistically
significant doubling in both plasma insulin and C-peptide levels
(Figures 7D and 7E). Hematoxylin and eosin staining (H&E) and
insulin staining of whole pancreas sections revealed increased
islet size in KIRA6-treated animals (Figures 7F and 7G). Insu-
lin-positive islet areas remained significantly higher in the
KIRA6-treated group 18 days after stopping injections
(Figure 7H).
DISCUSSION
In the baker’s yeast S. cerevisiae, the UPR is a homeostatic
signaling pathway controlled by IRE1-mediated splicing of an
mRNA encoding an adaptive transcription factor called Hac1
(Cox andWalter, 1996). Following this paradigm from this unicel-
lular eukaryote, reports have suggested that the signaling out-
puts of mammalian IRE1a are likewise solely restricted to
restoring homeostasis and promoting survival under ER stress
(Lin et al., 2007). Furthermore, these models posit that, when
ER stress becomes irremediable, IRE1a’s prosurvival signaling
through XBP1 splicing circumstantially wanes (through an un-
known mechanism), even as apoptotic outputs from PERK rise
to promote cell death, without further opposition by IRE1a (Lin
et al., 2009). These arguments therefore predict that sustained
IRE1a activation (even if artificially imposed) should universally
promote cell survival under ER stress, whereas genetic or
pharmacological inhibition of IRE1a should hasten cell death.
Through forcibly activating and inhibiting IRE1a in a variety of
cell systems and animal models, here we generated extensive(I642G) cells induced by Dox (1 mg/ml) for 24 hr, then 1NM-PP1 (0.5 mM) /+
Tm (0.5 mg/ml), 1NM-PP1 (1 mM), and indicated [KIRA6].
ity in IRE1a* (I642G). Data are plotted as mean ± SD. *p < 0.05 and **p < 0.01.
Figure 5. KIRA6 Reduces ER Stress-Induced Death of Cultured Cells and in Pancreatic Islet Explants
(A) Immunoblots for total and phospho-IRE1a in INS-1 cells pretreated for 1 hr with indicated [KIRA6] or 10 mM (NMe)KIRA6 and then Tg (1 mM) for 2 hr.
(B) Agarose gel of XBP1 cDNA amplicons from INS-1 cells pretreated with indicated [KIRA6] for 1 hr or 10 mM (NMe)KIRA6, followed by 0.5 mg/ml Tm for 8 hr.
(C) Ratios of XBP1S over (XBP1S + XBP1U) from (B).
(D) qPCR for Ins1 mRNA (normalized to no Tm) in INS-1 cells pretreated for 1 hr with indicated [KIRA6] and then 12 hr in Tm (0.5 mg/ml).
(E) Immunofluorescence: insulin (green) and TXNIP (red) in islets of C57BL/6 mice under 0.5 mg/ml Tm /+ 0.5 mM KIRA6 for 16 hr.
(F) IL-1b secretion from THP-1 cells after 4 hr /+ 0.5 mM KIRA6, 5 mg/ml Tm, 1 mM Tg, or 5 mM ATP.
(G) Ki67+ INS1 cells under 0.25 mg/ml BFA /+ 0.5 mM KIRA6 for 48 hr.
(H) Proliferating mouse islet b cells under 0.5 mg/ml Tm /+ 0.5 mM KIRA6 for 48 hr (nuclei double-positive for EdU and b cell nuclear marker, Nkx6.1, over total
Nkx6.1 positive nuclei).
(I) Annexin-V staining of INS-1 cells treated with 0.25 mg/ml BFA and indicated [KIRA6] for 72 hr.
(legend continued on next page)
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data that refute these aforementioned predictions to instead
support opposite conclusions.
An alternative model that we previously proposed (Han
et al., 2009) and mechanistically substantiated here is that
IRE1a switches outputs depending on the level of ER stress.
Under low, manageable levels of ER stress, adaptive UPR
signaling promotes secretory homeostasis, partly through
IRE1a-mediated splicing of XBP1 mRNA and consequent
XBP1s outputs. Likewise, pre-emptive PERK activation affords
a measure of cytoprotection against subsequent ER stress by
attenuating translation (Lu et al., 2004), as does precondition-
ing with 1NM-PP1-bound IRE1a (I642G) to transiently stabilize
an intermediate activation mode of the RNase confined to
XBP1 splicing (Han et al., 2008).
However, under high ER stress, IRE1a acquires endonucleo-
lytic activity against a large plethora of RNA targets, first identi-
fied in D. melanogaster and termed RIDD (Hollien and Weiss-
man, 2006), including ER-localized mRNAs and noncoding
RNAs in mammals (Han et al., 2009; Hollien et al., 2009; Lerner
et al., 2012; Upton et al., 2012). These extra-XBP1 RNA cleav-
age events precede and closely track with entry of ER-stressed
cells into apoptosis, and we showed here that their amelioration
with small-molecule inhibitors of IRE1a kinase/RNase inhibits
apoptosis. Thus, rather than have the two UPR kinases working
in opposition, multiple lines of evidence suggest that a contin-
uum of graded activation states (dependent upon the strength
of upstream stress) is available to either IRE1a or PERK, both
of which under high activation undergo switch-like conversion
from promoting homeostasis to promoting cell death (Han
et al., 2009; Lin et al., 2009). Similar switching mechanisms
occur in other cell-surface death receptors that respond diver-
gently depending on the strength or context of upstream inputs
(Festjens et al., 2007; Ofengeim and Yuan, 2013).
Further supporting a model of binary, rather than unitary out-
puts, three postulates that we posed and tested reasonably
establish causality between IRE1a hyperactivation and cell
death:
(1) First, forced hyperactivation of IRE1a’s RNase should suf-
fice to lead cells into the terminal UPR and along a continuum
of destructive outcomes, including proliferative blocks, loss of
differentiated cell identity, and eventually into apoptosis. In line
with this expectation, past a critical oligomerization threshold,
IRE1a’s RNase degrades key mediators of specialized cell
function, including abundant insulin-encoding mRNAs in
pancreatic b cells and rhodopsin mRNAs in retinal photore-
ceptor cells (both ER localized). Also, as previously shown,
mRNAs encoding ER-resident enzymatic activities are also tar-
geted by hyperactive IRE1a RNase, potentially compromising
ER function (Han et al., 2009). Thus, at high activation, IRE1a’s
adaptive outputs become overshadowed by its destructive(J) Immunofluorescence images of C57BL/6 islets treated with 0.5 mg/ml Tm /+
(red). Quantification of TUNEL+ b cells (white arrows) normalized to DAPI+ cells.
(K) Glucose-stimulated insulin secretion (GSIS) by C57BL/6 islets after 0.5 mg/ml
(L) Immunoblots for alpha-1 antitrypsin in HEK293 cells transfected with pCDNA3
Three independent biological samples were used for XBP1 splicing, qPCR, Anne
*p < 0.05 and **p < 0.01.
See also Figure S5.
544 Cell 158, 534–548, July 31, 2014 ª2014 Elsevier Inc.outputs and further amplified downstream by TXNIP, causing
IL-1b secretion, sterile inflammation/pyroptosis (linked to both
types 1 and 2 diabetes) (Lerner et al., 2012; Schroder et al.,
2010), and JNK signaling (Urano et al., 2000). Further linking
IRE1a to cell death, IRE1a cancer mutants show defective
homo-oligomerization and RNase activity, which may allow
the terminal UPR to become disabled or co-opted for survival
advantage. Indeed, proliferative blocks normally imposed
through IRE1a are defeated in the cancer mutants. Given these
results, future studies of mutated IRE1a in cancer are
warranted.
(2) Second, a class of IRE1a inhibitors that disrupt oligomer-
ization should reduce RNase activity and terminal UPR events
in tandem. Unique among multidomain kinases, the mecha-
nistic relationship between IRE1a’s kinase and RNase allows
divergent small-molecule allosteric control (Wang et al.,
2012). Whereas both are ATP competitive, IRE1a type I kinase
inhibitors increase oligomerization to increase RNase activity,
whereas IRE1a type II kinase inhibitors decrease oligomeriza-
tion to decrease RNase activity. Here, we developed and
tested the effects of KIRA6, an advanced IRE1a type II kinase
inhibitor. Given that KIRA6 has a favorable therapeutic index
and shows IRE1a ON-target effects, we predicted that it
would reduce cell death under ER stress. Remarkably, block-
ing IRE1a with KIRA6 raises the apoptotic threshold and en-
hances survival during ongoing upstream ER stress, indicating
that destructive signaling rather than a compromised ER
microenvironment per se promotes cell death (Figure 7I).
Although poly-pharmacological toxicity precluded testing
ON-target effects of APY29, our results justify development
and testing of nontoxic type I kinase inhibitors against IRE1a
cancer mutants.
(3) Third, blocking IRE1awith KIRA6 should protect against ER
stress-mediated cell degeneration in vivo, leading not only to
increased cell survival but also to preserved physiological func-
tion. Consistent with this, in various cell types and explants,
KIRA6 not only reduced cell loss under acute ER stress but
also prevented proliferative blocks and preserved function
(e.g., GSIS). Encouraged by these data, we tested KIRA6 in
rodent models of chronic ER stress-induced retinal degenera-
tion. P23H rats intravitreally treated with KIRA6 had significantly
preserved photoreceptor numbers, and in the Tm coinjection
model, functional protection was found. Finally, systemic admin-
istration of KIRA6 in the Akita diabetic mouse significantly
reduced random blood glucose levels, improved glucose toler-
ance acutely, preserved b cells, and elevated blood insulin and
C-peptide levels. Remarkably, beneficial effects persisted even
several weeks after stopping treatment. To our knowledge, this
is the first work showing small-molecule efficacy in the highly
penetrant Akita genetic model.0.5 mM KIRA6 for 16 hr. Costained for DAPI (blue), insulin (green), and TUNEL
Tm /+ 0.5 mM KIRA6 for 16 hr; [Glucose] was 2.5 mM or 16.7 mM for 60 min.
.1-a1hAT-NHK and then treated with KIRA6 (1 mM)/+ Tm (0.5 mg/ml) for 20 hr.
xin V, and immunofluorescence experiments. Data are plotted as mean ± SD.
Figure 6. Intravitreal KIRA6 Preserves Photoreceptor Cell Numbers and Function under ER Stress
(A–C) (A) Percentage of XBP1 splicing in SD rat retinas 72 hr postintravitreal—and qPCR for TXNIP mRNA (B) and rhodopsin mRNA (C) 96 hr postintravitreal—
injection of 20 mg/ml Tm /+ 10 mM KIRA6.
(D–G) (D) Primer extension mapping of IRE1a cleavage site in rhodopsin RNA with alignment of rhodopsin and XBP1 mRNA (E). Urea PAGE of cleavage
of 32P-labeled rhodopsin mRNA by IRE1a* with indicated [KIRA6], with IC50 (G); black arrow: intact RNA; red arrow: cleaved RNA.
(H) OCT images and histological sections of SD rats 7 days postintravitreal injection of 20 mg/ml Tm /+ 10 mM KIRA6; bars and asterisks denote ONLs.
(I) SD rats intravitreally injected at P21with 2 ml Tm or DMSO to achieve indicated [Tm]; ERG measurements at a light intensity of 0 dB recorded at P28.
(J) Representative scotopic ERG at a light intensity of 0 dB from a SD rat treated with Tm (3 mg/ml) ± KIRA6 (10 mM) at P21 and analyzed at P28.
(K) Quantified a and b wave amplitudes of 0 dB scotopic ERGs from SD rats treated with DMSO or Tm (3 mg/ml) ± KIRA6 (10 mM) at P21 and analyzed at P28.
See also Figure S6.Thus, we conclude that IRE1a exerts powerful effects on cell
fate and function under ER stress and that its kinase domain pre-
sents an attractive target for small-molecule modulation. In sum-
mary, KIRA6, an advanced small-molecule kinase inhibitor of
IRE1a, reduces cell death in several disease-relevant models
of ER stress-induced cell degeneration. While homozygous
deletion of either Ire1a or Xbp1 impedes embryogenesis andsecretory cell development (Reimold et al., 2001; Tirasophon
et al., 1998; Urano et al., 2000; Zhang et al., 2005), the ability
to titrate down IRE1a’s catalytic activities with a small mole-
cule provides an opportunity to uncouple extra-XBP1 destruc-
tive outputs from XBP1-dependent adaptation. From this
work, we propose the existence of a natural therapeutic
window for IRE1a inhibition owing to the higher oligomeric stateCell 158, 534–548, July 31, 2014 ª2014 Elsevier Inc. 545
Figure 7. Systemic KIRA6 Attenuates b Cell Functional Loss, Increases Insulin Levels, and Ameliorates Hyperglycemia in the Akita Mouse
(A) Random AM blood glucose (BG) levels in male Ins2+/Akita mice i.p. injected for 37 days b.i.d. with KIRA6 (5 mg/kg) (n = 6) or vehicle (n = 6) starting at P21
(i.e., day 1). BGs (mean ± SEM), also analyzed by two-way RM ANOVA; p = 0.0122.
(B) Cohort body weights at day 49.
(C) Glucose tolerance tests on day 49 (12 day postinjections) of O/N fasted Ins2+/Akita mice (P53) after i.p. (2 g/kg) glucose (KIRA6 n = 6, vehicle n = 3).
(D and E) Random insulin and C-peptide levels in Ins2+/Akita mice on day 58 (21 days postinjections). KIRA6 (5 mg/kg) (n = 5) and vehicle (n = 4).
(F) Whole pancreatic histological sections from Ins2+/Akita mice on day 53 (15 days postinjections). Islets delineated by dashed outline.
(G) Immunofluorescence micrographs of samples in (F): costained for DAPI (blue) and insulin (green) with merge.
(H) Total b cell area as a percentage of total pancreas area on day 55 (18 day postinjections). KIRA6 (5 mg/kg) (n = 6) and vehicle (n = 3).
(I) Model of how KIRA6 prevents the terminal UPR by inhibiting IRE1a oligomers. Data are plotted as mean ± SD. *p < 0.05 and ** < 0.01.
See also Figure S7.needed for extra-XBP1 endonucleolytic activation (RIDD); thus,
lower concentrations of IRE1a type II kinase inhibitors block
RIDD while maintaining XBP1 splicing (Figure 5D). Subsequent
work is necessary to understand the consequences of long-546 Cell 158, 534–548, July 31, 2014 ª2014 Elsevier Inc.term IRE1a inhibition. Although further medicinal chemistry
to optimize KIRA6 is beyond the scope of this study, such
efforts may lead to first-in-class agents capable of preventing
cell loss and affording therapeutic benefit in myriad human
degenerative diseases, including retinitis pigmentosa and
diabetes.
EXPERIMENTAL PROCEDURES
Tissue Culture, ER Stress Agents, and Small Molecules
Generation of isogenic, stable INS-1 lines was described previously (Han et al.,
2009) (see also Extended Experimental Procedures). Thapsigargin (Tg), Brefel-
din A (BFA), and Dox were purchased from Sigma-Aldrich. Tunicamycin (Tm)
was purchased from Millipore. APY29, KIRA6, (NMe)KIRA6 1NM-PP1, and
STF-083010 were synthesized in house (see Extended Experimental Proce-
dures for synthesis, purification, and purity determination methods of small
molecules).
Western Blots and Antibodies
For protein analysis, cells were lysed in M-PER buffer (Thermo Scientific) plus
complete EDTA-free protease inhibitor (Roche) and phosphatase inhibitor
cocktail (Sigma). Protein concentration was determined using BCA Protein
Assay (Thermo). Western blots were performed using 10% and 12% Bis-Tris
precast gels (NuPage) on Invitrogen XCell SureLock Mini-Cell modules. Gels
were run using MES buffer and transferred onto nitrocellulose transfer mem-
brane using an XCell II Blot Module. Antibody binding was detected by using
near-infrared-dye-conjugated secondary antibodies (Li-Cor) on the LI-COR
Odyssey scanner or visualized by capturing on a CL-XPosure film using ECL
SuperSignal West Dura Extended Duration Substrate (both from Thermo
Scientific). See Extended Experimental Procedures for details of the anti-
bodies used.
RNA Isolation, Quantitative Real-Time PCR, and Primers
RNA was isolated from whole cells using either QIAGEN RNeasy kits or Trizol
(Invitrogen). TissueLyser II (QIAGEN) was used for RNA isolation from liver and
retina. For standard mRNA detection, generally 1 mg total RNA was reverse
transcribed using the QuantiTect Reverse Transcription Kit (QIAGEN). For
Q-PCR, we used SYBR green (QIAGEN) and StepOnePlus Real-Time PCR
System (Applied Biosystems). Gene expression levels were normalized to
GAPDH or Actin. See Extended Experimental Procedures for primer se-
quences used for Q-PCRs and for details of XBP1 mRNA splicing.
In Vitro IRE1a* Crosslinking, RNase, and Kinase Assays
See Wang et al. (2012) and the Extended Experimental Procedures for details
of RNase, kinase, and oligomerization assays.
Flow Cytometry
For assaying apoptosis by Annexin V staining, cells were plated in 12-well
plates overnight. Cells were then treated with various ER stress agents for indi-
cated times. On the day of analysis, cells were trypsinized and washed in PBS
and resuspended in Annexin V binding buffer with Annexin-V FITC (BD
PharMingen). Flow cytometry was performed on a Becton Dickinson LSRII
flow cytometer.
Islet Staining
Islets were extracted from C57BL/6 mice using previously reported methods
(Szot et al., 2007). Approximately 150 islets were cultured for each condition
in triplicate. Nondiabetic human islets were obtained from Prodo Labs (Irvine)
and cultured in Prodo Islet Medium (PIM from Prodo Labs). Islets were stained
with TUNEL using ApopTag Red In Situ Apoptosis Detection Kit (Millipore)
according to the manufacturer’s instructions. Islets were also costained with
anti-TXNIP (MBL International), guinea pig anti-insulin (Zymed), DAPI (Sigma),
and goat anti-guinea pig secondary (Rockland) before mounting onto slides
with VectaShield (Vector Laboratories). At least 10 islets and >500 b cell nuclei
were counted per group, in triplicate. See also Extended Experimental Proce-
dures for details of fixation and staining.
Intravitreal Injections of Small Molecules
2 ml was injected intravitreally into each eye to achieve indicated final concen-
trations based on known rat vitreous volumes. Tm (20 mg/ml final) ± KIRA6(10 mM final) was injected into SD rats at P21 with equivalent DMSO as vehicle
control. Retinas were collected at 72 and 96 hr after injections in Trizol (Invitro-
gen) for qPCR. Eyes were examined by optical coherence tomography (OCT)
7 days postinjection and then collected for morphological analysis. P23H rats
were injected with KIRA6 (10 mM final) or DMSO vehicle at P9 and P15, and
eyes were examined at P40 by OCT and by morphological analysis. See
Extended Experimental Procedures for details of image guided (OCT),
morphological analysis, and electroretinography (ERG).
Mouse Systemic Injections
Male Ins2+/Akita mice were injected i.p. with KIRA6 in a 2 mg/ml solution made
of 3% ethanol: 7% Tween-80: 90% saline twice a day (b.i.d.). Same solution
without KIRA6 is denoted as vehicle. C567BL/6 mice were also injected with
the same KIRA6 solution and indicated doses of Tm for liver analysis. See
Extended Experimental Procedures for details of islet explant experiments,
GSIS, proliferation studies, blood glucose determination, glucose tolerance
tests, insulin and C-peptide measurements, and b cell area determination.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and sevenmovies and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.07.002.
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